Novonesis (Novozymes) B (OCSE:NSIS B) Marketable Securities : kr52 Mil (As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Novonesis (Novozymes) B Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Novonesis (Novozymes) B's Marketable Securities for the quarter that ended in Mar. 2025 was kr52 Mil.

Novonesis (Novozymes) B's annual Marketable Securities declined from Dec. 2022 (kr80 Mil) to Dec. 2023 (kr40 Mil) and declined from Dec. 2023 (kr40 Mil) to Dec. 2024 (kr30 Mil).

Novonesis (Novozymes) B Marketable Securities Historical Data

The historical data trend for Novonesis (Novozymes) B's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Marketable Securities Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

118.98

74.99

79.88

40.25

29.83

Novonesis (Novozymes) B Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															40.25	-	17.17	29.83	52.21

Novonesis (Novozymes) B Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Novonesis (Novozymes) B (OCSE:NSIS B) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Novonesis (Novozymes) B Marketable Securities Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OCSE:NSIS B) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NVZMF:USA NSISBc:UK 0Q4U:UK NZM:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines